# Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

> **NCT00644969** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 128 (actual)

## Conditions studied

- Smoking Cessation

## Interventions

- **DRUG:** placebo
- **DRUG:** varenicline (CP-526,555)

## Key facts

- **NCT ID:** NCT00644969
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2011-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00644969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00644969, "Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00644969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*